124045 20241125101130.0 doi 10.1016/j.ijpharm.2023.122589 sideral 132671 ART-2023-132671 eng Paz-Artigas, L. (orcid)0000-0001-6139-5905 Current approaches for the recreation of cardiac ischaemic environment in vitro 2023 Access copy available to the general public Unrestricted Myocardial ischaemia is one of the leading dead causes worldwide. Although animal experiments have historically provided a wealth of information, animal models are time and money consuming, and they usually miss typical human patient’s characteristics associated with ischemia prevalence, including aging and comorbidities. Generating reliable in vitro models that recapitulate the human cardiac microenvironment during an ischaemic event can boost the development of new drugs and therapeutic strategies, as well as our understanding of the underlying cellular and molecular events, helping the optimization of therapeutic approaches prior to animal and clinical testing. Although several culture systems have emerged for the recreation of cardiac physiology, mimicking the features of an ischaemic heart tissue in vitro is challenging and certain aspects of the disease process remain poorly addressed. Here, current in vitro cardiac culture systems used for modelling cardiac ischaemia, from self-aggregated organoids to scaffold-based constructs and heart-on-chip platforms are described. The advantages of these models to recreate ischaemic hallmarks such as oxygen gradients, pathological alterations of mechanical strength or fibrotic responses are highlighted. The new models represent a step forward to be considered, but unfortunately, we are far away from recapitulating all complexity of the clinical situations. info:eu-repo/grantAgreement/EC/H2020/778354/EU/Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine/CISTEM This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 778354-CISTEM info:eu-repo/grantAgreement/EC/H2020/829010/EU/Advanced and versatile PRInting platform for the next generation of active Microfluidic dEvices/PRIME This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 829010-PRIME info:eu-repo/grantAgreement/EC/H2020/874827/EU/Computational biomechanics and bioengineering 3D printing to develop a personalized regenerative biological ventricular assist device to provide lasting functional support to damaged hearts/BRAV3 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 874827-BRAV3 info:eu-repo/grantAgreement/ES/ISCIII/PI19-01350 info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 5.3 2023 PHARMACOLOGY & PHARMACY 35 / 354 = 0.099 2023 Q1 T1 0.954 2023 Pharmaceutical Science 2023 Q1 10.7 2023 info:eu-repo/semantics/review info:eu-repo/semantics/publishedVersion Montero-Calle, P. Iglesias-García, O. Mazo, M. M. Ochoa, I. Universidad de Zaragoza (orcid)0000-0003-2410-5678 Ciriza, J. Universidad de Zaragoza (orcid)0000-0002-8666-622X 1003 443 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Histología 632 (2023), 122589 [17 pp.] Int. j. pharm. International Journal of Pharmaceutics 0378-5173 4008297 http://zaguan.unizar.es/record/124045/files/texto_completo.pdf Versión publicada 2422429 http://zaguan.unizar.es/record/124045/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:124045 articulos driver 2024-11-22-11:58:44 ARTICLE